Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 935 participants.

Also called NCT04273945

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 935 participants (enrolled count) (from the registry)
Sponsor
  • Actelion Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04273945
  • EudraCT 2019-002533-11
  • EU CT 2024-515669-32-00
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Austria, Belarus, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Czechia, Denmark, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, Norway, Poland, Portugal, Russia, Saudi Arabia, Serbia, Singapore, Slovakia, South Africa, South Korea, Spain, Sweden, Taiwan, Thailand, Türkiye, Ukraine, United Kingdom, Vietnam (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT04273945. Randomized; triple masking; primary purpose treatment. Start 2020-06-30 (actual); primary completion 2025-10-07 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
Acronym
UNISUS
Condition
Pulmonary Arterial Hypertension
Intervention (Drug)
Macitentan 10 mg
Intervention (Drug)
Macitentan 37.5 mg
Intervention (Drug)
Macitentan 75 mg
Intervention (Drug)
Placebo
Lead sponsor
Actelion (class: industry)

Record details

Record id
cardio:ct-nct04273945
Content hash
e61a0d2277800ba7625e11d7023e1a65bb2b86b32997e0a5c8130c6e3558d666